{"id":540977,"date":"2021-04-28T18:08:01","date_gmt":"2021-04-28T18:08:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=540977"},"modified":"2021-04-28T18:08:01","modified_gmt":"2021-04-28T18:08:01","slug":"neuromyelitis-optica-competitive-landscape-emerging-therapiesa-and-pipeline-insights-2021-neuromyelitis-optica-pipeline-analysis-2021-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/neuromyelitis-optica-competitive-landscape-emerging-therapiesa-and-pipeline-insights-2021-neuromyelitis-optica-pipeline-analysis-2021-delveinsight_540977.html","title":{"rendered":"Neuromyelitis Optica Competitive Landscape, Emerging Therapiesa and Pipeline Insights 2021 | Neuromyelitis Optica Pipeline Analysis, 2021 | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1619584084.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Neuromyelitis Optica Competitive Landscape, Emerging Therapiesa and Pipeline Insights 2021 | Neuromyelitis Optica Pipeline Analysis, 2021 | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1619584084.jpeg\" alt=\"Neuromyelitis Optica Competitive Landscape, Emerging Therapiesa and Pipeline Insights 2021 | Neuromyelitis Optica Pipeline Analysis, 2021 | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">&#8220;Neuromyelitis Optica Pipeline Insights, 2021&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Neuromyelitis Optica market. A detailed picture of the Neuromyelitis Optica pipeline landscape is provided, which includes the disease overview and Neuromyelitis Optica treatment guidelines. <\/p>\n<\/div>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">DelveInsight launched a new report on <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/neuromyelitis-optica-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Neuromyelitis Optica Pipeline Insights, 2021<\/strong><\/a>.<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><strong>Neuromyelitis Optica (NMO)<\/strong> is a central nervous system disorder that primarily affects the eye nerves (optic neuritis) and the spinal cord (myelitis). NMO is also known as neuromyelitis optica spectrum disorder or Devic&#8217;s disease. It occurs when your body&#8217;s immune system reacts against its own cells in the central nervous system, mainly in the optic nerves and spinal cord, but sometimes in the brain.<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/neuromyelitis-optica-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Neuromyelitis Optica Pipeline Insight, 2021<\/strong><\/a>&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;<strong>Neuromyelitis Optica&nbsp;<\/strong>market. A detailed picture of the&nbsp;<strong>Neuromyelitis Optica&nbsp;<\/strong>pipeline landscape is provided, which includes the disease overview and&nbsp;<strong>Neuromyelitis Optica&nbsp;<\/strong>treatment guidelines.<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/f1660f56f0db9e854f916db372205289.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/neuromyelitis-optica-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Neuromyelitis Optica Key Pharma Players involved:<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>1. Pfizer<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>2. Teva<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>3. And others.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample pages of the report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/neuromyelitis-optica-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/neuromyelitis-optica-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li class=\"ql-align-justify\">The&nbsp;<strong>Neuromyelitis Optica&nbsp;<\/strong>report provides an overview of&nbsp;<em>therapeutic pipeline activity and therapeutic assessment of the products<\/em>&nbsp;by development stage, product type, route of administration, molecule type, and MOA type&nbsp;<em>for&nbsp;<\/em><strong>Neuromyelitis Optica&nbsp;<\/strong>across the complete product development cycle, including all clinical and nonclinical stages.<\/li>\n<li class=\"ql-align-justify\">It comprises of&nbsp;<em>detailed profiles of&nbsp;<\/em><strong>Neuromyelitis Optica&nbsp;<\/strong><em>therapeutic products<\/em>&nbsp;with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/li>\n<li class=\"ql-align-justify\">Detailed&nbsp;<strong>Neuromyelitis Optica&nbsp;<\/strong><em>research and development progress and trial details<\/em>, results wherever available, are also included in the pipeline study.<\/li>\n<li class=\"ql-align-justify\"><em>Coverage of dormant and discontinued pipeline project<\/em>s along with the reasons if available across&nbsp;<strong>Neuromyelitis Optica<\/strong>.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of contents:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1. Report Introduction<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>2. Neuromyelitis Optica&nbsp;<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><strong>3. Neuromyelitis Optica&nbsp;Current Treatment Patterns<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><strong>4. Neuromyelitis Optica&nbsp;&#8211; DelveInsight&#8217;s Analytical Perspective<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><strong>5. Therapeutic Assessment<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><strong>6. Neuromyelitis Optica Late Stage Products (Phase-III)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>7. Neuromyelitis Optica Mid Stage Products (Phase-II)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>8. Early Stage Products (Phase-I)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>9. Pre-clinical Products and Discovery Stage Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>10. Inactive Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>11. Dormant Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>12. Neuromyelitis Optica Discontinued Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>13. Neuromyelitis Optica&nbsp;Product Profiles<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><strong>14. Neuromyelitis Optica&nbsp;Key Companies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>15. Neuromyelitis Optica&nbsp;Key Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>16. Dormant and Discontinued Products<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><strong>17. Neuromyelitis Optica&nbsp;Unmet Needs<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>18. Neuromyelitis Optica&nbsp;Future Perspectives<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>19. Neuromyelitis Optica&nbsp;Analyst Review&nbsp;&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>20. Appendix<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>21. Report Methodology<\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><strong>Download free sample pages of the report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/neuromyelitis-optica-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><span data-sheets-value=\"{\" data-sheets-userformat=\"{\">https:\/\/www.delveinsight.com\/sample-request\/neuromyelitis-optica-pipeline-insight<\/span><\/a><\/strong><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\"><strong>Contact us:<br \/><\/strong>Shruti Thakur<br \/>info@delveinsight.com<br \/>+919650213330<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=neuromyelitis-optica-competitive-landscape-emerging-therapiesa-and-pipeline-insights-2021-neuromyelitis-optica-pipeline-analysis-2021-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=neuromyelitis-optica-competitive-landscape-emerging-therapiesa-and-pipeline-insights-2021-neuromyelitis-optica-pipeline-analysis-2021-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP &#8220;Neuromyelitis Optica Pipeline Insights, 2021&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Neuromyelitis Optica market. A detailed picture of the Neuromyelitis Optica pipeline landscape is provided, which &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/neuromyelitis-optica-competitive-landscape-emerging-therapiesa-and-pipeline-insights-2021-neuromyelitis-optica-pipeline-analysis-2021-delveinsight_540977.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-540977","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/540977","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=540977"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/540977\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=540977"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=540977"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=540977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}